142 related articles for article (PubMed ID: 19863879)
1. Optimal blood pressure control versus additional immunosuppressive therapy in idiopathic membranous nephropathy - a retrospective analysis.
Dikow R; Quentmeier P; Schwenger V; Waldherr R; Andrassy K; Ritz E; Zeier M
Clin Nephrol; 2009 Nov; 72(5):366-72. PubMed ID: 19863879
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.
Liang Q; Li H; Xie X; Qu F; Li X; Chen J
Ren Fail; 2017 Nov; 39(1):512-518. PubMed ID: 28562168
[TBL] [Abstract][Full Text] [Related]
3. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.
Ruggenenti P; Mosconi L; Vendramin G; Moriggi M; Remuzzi A; Sangalli F; Remuzzi G
Am J Kidney Dis; 2000 Mar; 35(3):381-91. PubMed ID: 10692263
[TBL] [Abstract][Full Text] [Related]
4. Urinary N-acetyl-β-glucosaminidase and estimated Glomerular filtration rate may identify patients to be treated with immuno-suppression at diagnosis in idiopathic membranous nephropathy.
Bazzi C; Usui T; Rizza V; Casellato D; Gallieni M; Nangaku M
Nephrology (Carlton); 2018 Feb; 23(2):175-182. PubMed ID: 27764902
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC;
Nephron; 2015; 130(3):159-68. PubMed ID: 26087670
[TBL] [Abstract][Full Text] [Related]
6. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.
Goumenos DS; Ahuja M; Davlouros P; El Nahas AM; Brown CB
Clin Nephrol; 2006 May; 65(5):317-23. PubMed ID: 16724651
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
Busch M; Gerth J; Ott U; Schip A; Haufe CC; Gröne HJ; Wolf G
Med Klin (Munich); 2008 Jul; 103(7):519-24. PubMed ID: 18604487
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.
Dussol B; Morange S; Burtey S; Indreies M; Cassuto E; Mourad G; Villar E; Pouteil-Noble C; Karaaslan H; Sichez H; Lasseur C; Delmas Y; Nogier MB; Fathallah M; Loundou A; Mayor V; Berland Y
Am J Kidney Dis; 2008 Oct; 52(4):699-705. PubMed ID: 18585835
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome.
Kosmadakis G; Filiopoulos V; Georgoulias C; Tentolouris N; Michail S
Scand J Urol Nephrol; 2010 Sep; 44(4):251-6. PubMed ID: 20201749
[TBL] [Abstract][Full Text] [Related]
11. Membranous nephropathy with crescents: a series of 19 cases.
Rodriguez EF; Nasr SH; Larsen CP; Sethi S; Fidler ME; Cornell LD
Am J Kidney Dis; 2014 Jul; 64(1):66-73. PubMed ID: 24709471
[TBL] [Abstract][Full Text] [Related]
12. Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy?
Ahuja M; Goumenos D; Shortland JR; Gerakis A; Brown CB
Am J Kidney Dis; 1999 Sep; 34(3):521-9. PubMed ID: 10469864
[TBL] [Abstract][Full Text] [Related]
13. [Membranous glomerulonephritis].
Scheidat S; Stahl RA
Internist (Berl); 2003 Sep; 44(9):1120-30. PubMed ID: 14566465
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents.
Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial.
Praga M; Barrio V; Juárez GF; Luño J;
Kidney Int; 2007 May; 71(9):924-30. PubMed ID: 17377504
[TBL] [Abstract][Full Text] [Related]
16. Membranous nephropathy in children: clinical presentation and therapeutic approach.
Menon S; Valentini RP
Pediatr Nephrol; 2010 Aug; 25(8):1419-28. PubMed ID: 19908069
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome.
Chen A; Frank R; Vento S; Crosby V; Chandra M; Gauthier B; Valderrama E; Trachtman H
BMC Nephrol; 2007 Aug; 8():11. PubMed ID: 17683621
[TBL] [Abstract][Full Text] [Related]
18. Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort.
du Buf-Vereijken PW; Feith GW; Hollander D; Gerlag PG; Wirtz JJ; Noordzij TC; Wetzels JF;
QJM; 2004 Jun; 97(6):353-60. PubMed ID: 15152109
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine treatment in idiopathic membranous nephropathy nephrotic syndrome in adults: a retrospective study spanning 15 years.
Tao JL; Liu LL; Wen YB; Gao RT; Li H; Li MX; Li XM; Li XW
Chin Med J (Engl); 2011 Nov; 124(21):3490-4. PubMed ID: 22340164
[TBL] [Abstract][Full Text] [Related]
20. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.
Hofstra JM; Branten AJ; Wirtz JJ; Noordzij TC; du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2010 Jan; 25(1):129-36. PubMed ID: 19666912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]